HeartMate 3植入后严重头晕与晕厥需更换泵一例
本文报告一例HeartMate 3左心室辅助装置成功植入后出现严重难治性体位性头晕和晕厥的罕见并发症,患者最终通过将泵更换为HeartWare HVAD使症状缓解。随着HM3植入量增加,此类罕见意外并发症可能更多出现。
要点
- HM3植入后严重难治性体位性头晕和晕厥是罕见并发症。
- 该例患者最终需更换为HeartWare HVAD才使症状缓解。
- 大样本试验难以捕获此类罕见意外并发症。
核心结论
- HM3植入后可出现严重难治性体位性头晕和晕厥这一罕见并发症,需更换为HeartWare HVAD方能缓解症状。
研究设计与样本
- 单例病例报告,描述一例HM3成功植入后出现严重难治性体位性头晕和晕厥并最终更换泵的患者。
主要发现
- 患者HM3植入成功后出现严重难治性体位性头晕和晕厥。
- 最终将泵更换为HeartWare HVAD后症状缓解。
临床怎么用
- HM3植入后出现严重难治性体位性头晕和晕厥时,应考虑罕见装置相关并发症并评估更换泵的可能性。
局限性
- 单例病例报告,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Implantation of the HeartMate 3 (HM3) left ventricular assist device (Abbott Laboratories, Lake Bluff, IL) continues to increase as the results of European and U.S. clinical trials become available. Although the large trials adequately capture the more common and expected outcomes, rare and unexpected clinical complications will continue to appear with higher volumes of implantation. This report describes a rare complication of severe refractory postural dizziness and syncope after successful implantation of an HM3 in a patient who ultimately required pump exchange to a HeartWare HVAD (HeartWare, Framingham, MA) for resolution of symptoms.
引用
- Kagawa H, Coyan G, Davis K, et al. Severe Dizziness and Syncope After HeartMate 3 Implantation Requiring Pump Exchange. Ann Thorac Surg. 2019. PMID: 30853589. doi:10.1016/j.athoracsur.2019.01.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。